AMGN vs VRTX

Amgen (AMGN) and Vertex Pharmaceuticals (VRTX) compared side by side. Amgen (AMGN) is larger, with a market cap of $237.5B versus $132.8B for Vertex Pharmaceuticals, about 1.8 times the size. On trailing earnings, AMGN is cheaper at 27.3x versus 29.9x for VRTX.

Head to head

MetricAMGNVRTX
Market cap$237.5B$132.8B
P/E (TTM)27.3x29.9x
Forward P/E17.9x25.7x
Revenue (TTM)$38.1B$12.6B
Revenue growth9.5%12.5%
Gross margin71.9%55.0%
Operating margin35.5%38.1%
Free cash flow$10.2B$3.8B
Dividend yield2.29%None
1-year return+54.1%+24.0%
5-year return (annual)+19.7%+23.3%
Max drawdown-78%-92%
FI Handbook gradeB-B

Highlighted: the stronger figure on metrics where higher or lower is clearly better.

Growth of $10,000 (5 years, price only)

$10.0K
$20.0K
$30.0K
20222023202420252026
AMGNVRTX

AMGN vs VRTX FAQ

Which is bigger, AMGN or VRTX?

Amgen (AMGN) is larger, with a market cap of $237.5B versus $132.8B for Vertex Pharmaceuticals, about 1.8 times the size.

Is AMGN or VRTX cheaper?

On trailing earnings, AMGN is cheaper at 27.3x versus 29.9x for VRTX. A lower P/E can reflect slower expected growth, so compare growth and margins too.

Which stock performed better over the past year, AMGN or VRTX?

AMGN returned +54.1% over the past year including dividends, versus +24.0% for VRTX, through October 23, 2026.

Which pays a higher dividend, AMGN or VRTX?

AMGN yields 2.29%; VRTX does not pay a dividend.

Full pages: Amgen · Vertex Pharmaceuticals